Prothena Corporation plc - Ordinary Shares (PRTA): Price and Financial Metrics
PRTA Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for PRTA is 0 -- better than just 8.78% of US stocks.
- For PRTA, its debt to operating expenses ratio is greater than that reported by merely 15.79% of US equities we're observing.
- PRTA's price/sales ratio is 1,027.1; that's higher than the P/S ratio of 99.13% of US stocks.
- If you're looking for stocks that are quantitatively similar to Prothena Corp Public Ltd Co, a group of peers worth examining would be BCDA, MRKR, APTX, CYCN, and BLUE.
- Visit PRTA's SEC page to see the company's official filings. To visit the company's web site, go to www.prothena.com.
PRTA Stock Price Chart Interactive Chart >
PRTA Price/Volume Stats
| Current price | $23.96 | 52-week high | $28.66 |
| Prev. close | $23.37 | 52-week low | $9.25 |
| Day low | $22.99 | Volume | 208,332 |
| Day high | $24.44 | Avg. volume | 463,588 |
| 50-day MA | $22.05 | Dividend yield | N/A |
| 200-day MA | $14.54 | Market Cap | 958.54M |
Prothena Corporation plc - Ordinary Shares (PRTA) Company Bio
Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The company was founded in 2012 and is based in Dublin, Ireland.
Latest PRTA News From Around the Web
Below are the latest news stories about Prothena Corp Public Ltd Co that investors may wish to consider to help them evaluate PRTA as an investment opportunity.
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)DUBLIN, Ireland, April 07, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that in connection with hiring Dr. Hideki Garren as Prothena’s Chief Medical Officer, the compensation committee of the Company’s board of directors granted Dr. Garren, an option to purchase 250,000 ordinary shares of the Company. Such stock option has an exercise price per share equal to $24.90, which was the closing trading price on April 5, 2021, the date of the grant. In addition, in connection with hiring a new employee, the compensation committee of the Company’s board of directors granted the individ... |
Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical OfficerDr. Garren’s extensive expertise and successful track record of advancing neurology and rare disease programs through late-stage development, registration and launch supports Company’s transition to a fully-integrated R&D and commercial businessDUBLIN, Ireland, April 05, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced the appointment of Hideki Garren, MD, PhD, as Chief Medical Officer. Dr. Garren will lead the clinical and medical organizations to advance Prothena’s clinical pipeline. “Hideki brings valuable experience and expertise to our team as we look ahead towards transitioni... |
What Type Of Shareholders Make Up Prothena Corporation plc's (NASDAQ:PRTA) Share Registry?If you want to know who really controls Prothena Corporation plc ( NASDAQ:PRTA ), then you'll have to look at the... |
Prothena (PRTA) Stock Jumps 16.8%: Will It Continue to Soar?Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
Prothena Announces Pricing of Public Offering of 3,500,000 Ordinary SharesDUBLIN, Ireland, March 24, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that it priced an underwritten public offering of 3,500,000 of its ordinary shares at a price to the public of $20.75 per ordinary share, before the underwriting discount and estimated offering expenses. All of the ordinary shares in the offering were sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 525,000 of its ordinary shares. Net proceeds to Prothena from the ordinary shares to be sold by Prothena in the offering are expected to be $67... |
PRTA Price Returns
| 1-mo | -3.15% |
| 3-mo | 66.39% |
| 6-mo | 110.54% |
| 1-year | 104.44% |
| 3-year | -36.90% |
| 5-year | -49.38% |
| YTD | 99.50% |
| 2020 | -24.13% |
| 2019 | 53.69% |
| 2018 | -72.53% |
| 2017 | -23.79% |
| 2016 | -27.78% |
Continue Researching PRTA
Want to do more research on Prothena Corp plc's stock and its price? Try the links below:Prothena Corp plc (PRTA) Stock Price | Nasdaq
Prothena Corp plc (PRTA) Stock Quote, History and News - Yahoo Finance
Prothena Corp plc (PRTA) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...